Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.
- DOI
- 10.1016/s0140-6736(26)00459-9
- Published
- 2026 May 30
- Container
- Lancet (London, England)
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s0140-6736-26-00459-9,
title = {Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.},
author = {Cummings JL and Atri A and Sano M and Zetterberg H and Scheltens P and Knop FK and Johannsen P and Wichmann CA and Abschneider RM and Leon T and Feldman HH},
year = {2026},
journal = {Lancet (London, England)},
doi = {10.1016/s0140-6736(26)00459-9},
url = {https://doi.org/10.1016/s0140-6736(26)00459-9}
}RIS
TY - JOUR TI - Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. AU - Cummings JL AU - Atri A AU - Sano M AU - Zetterberg H AU - Scheltens P AU - Knop FK AU - Johannsen P AU - Wichmann CA AU - Abschneider RM AU - Leon T AU - Feldman HH PY - 2026 JO - Lancet (London, England) DO - 10.1016/s0140-6736(26)00459-9 UR - https://doi.org/10.1016/s0140-6736(26)00459-9 ER -
APA
JL, C., A, A., M, S., H, Z., P, S., FK, K., P, J., CA, W., RM, A., T, L., & HH, F. (2026). Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)00459-9
Source records
- pubmed · retrieved 2026-09-25T20:03:01.157Z